Loading, please wait ...


News Analytics

download.
GSK plc (LON/NYSE:GSK) has announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are at increased risk. This includes individuals with immunodeficiency or immunosuppression caused by known disease or therapy.

The Angle

Subject Matter

  • Healthcare 100.00%
    • Hospitals, doctors and medical care 64.38%
    • Health, disease and medicine 35.62%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions

Depth Chart

Here we provide depth for the multitude of dimensions lacing this article.

Connect your favorite information below with the lead sentence at the top of the page to build a mental model of the story.